切换至 "中华医学电子期刊资源库"
高级检索
中华临床医师杂志(电子版)

中华临床医师杂志(电子版) ›› 2023, Vol. 17 ›› Issue (10) : 1117 -1122. doi: 10.3877/cma.j.issn.1674-0785.2023.10.016

综述

miR-107与恶性肿瘤的研究进展
贺彬, 刘迅, 胡东辉†()   
  1. 430033　武汉，湖北省第三人民医院中医科
  • 收稿日期:2023-09-14 出版日期:2023-10-15
  • 通信作者: 胡东辉
  • 基金资助:
    湖北省中医药管理局2023-2024年度项目(ZY2023F032)

Progress in understanding of relationship between microRNA-107 and malignant tumors

Bin He, Xun Liu, Donghui Hu†()   

  1. Department of Traditional Chinese Medicine, Hubei Provincial Third People's Hospital, Wuhan 430033, China
  • Received:2023-09-14 Published:2023-10-15
  • Corresponding author: Donghui Hu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

贺彬, 刘迅, 胡东辉. miR-107与恶性肿瘤的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(10): 1117-1122.

Bin He, Xun Liu, Donghui Hu. Progress in understanding of relationship between microRNA-107 and malignant tumors[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(10): 1117-1122.

microRNA-107（miR-107）是具有多种疾病中起调节作用的miRNAs，在肿瘤细胞的生长、分化、增殖、发育、凋亡和代谢等多种过程中发挥重要作用，与多种肿瘤有关。在恶性肿瘤的发生发展中，有时作为癌基因促进恶性肿瘤的进展，有时又作为抑癌基因对恶性肿瘤起到抑制作用。总之，miR-107极有可能成为恶性肿瘤的诊断和治疗中新的生物标志物。本文对miR-107在不同系统恶性肿瘤中的作用及其可能机制进行具体阐述，并对其今后的研究方向提出自己的见解，旨在为miR-107在恶性肿瘤的诊治方面起到一定的推动作用。

关键词: miR-107, 恶性肿瘤, 癌基因, 抑癌基因

MicroRNA-107 (miR-107) is a microRNA that plays a regulatory role in various diseases. It plays an important role in various processes such as tumor cell growth, differentiation, proliferation, development, apoptosis, and metabolism, and is associated with various tumors. In the occurrence and development of malignant tumors, miR-107 may act as an oncogene to promote the progression of malignant tumors, and it can also act as a tumor suppressor gene to suppress malignant tumors. Thus, miR-107 is highly likely to become a new biomarker in the diagnosis and treatment of malignant tumors. This article provides a detailed explanation of the role and possible mechanisms of miR-107 in malignant tumors of different systems, and proposes our own insights into the future research directions, aiming to promote the diagnosis and treatment of malignant tumors.

Key words: miR-107, Cancer, Oncogenes, Tumor suppressor genes
1
Mourelatos Z, Dostie J, Paushkin S, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs [J]. Genes Dev, 2002, 16(6): 720-728.
2
Noren Hooten N, Abdelmohsen K, Gorospe M, et al. microRNA expression patterns reveal differential expression of target genes with age [J]. PLoS One, 2010, 5: e10724.
3
Turco C, Donzelli S, Fontemaggi G. miR-15/107 microRNA Gene Group: characteristics and functional implications in cancer [J]. Front Cell Dev Biol, 2020, 8: 427.
4
Jiang ZP, Zhou TB. Role of miR-107 and its signaling pathways in diseases[J]. J Recept Signal Transduct Res. 2014;34(5):338-41.
5
Finnerty JR. The miR-15/107 group of microRNAgenes:evolutionary biology,cellular functions,and roles in human diseases [J]. J Mol Biol, 2010, 402(3): 491-509.
6
Parvaee P, Sarmadian H, Khansarinejad B, et al. Plasma level of microRNAs,miR-107,miR-194 and miR-210 as potential biomarkers for diagnosis intestinal-type gastric cancer in human [J]. Asian Pac J Cancer Prev, 2019, 20(5): 1421-1426.
7
李钰娜, 黄燕, 栗学清. miR-107靶基因的生物学分析 [J]. 长治医学院学报, 2019, 33(2): 102-106.
8
Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013 [J]. Cancer Lett, 2017, 401: 63-71.
9
徐鑫鑫, 林兰, 王旭东, 等. miR-107在肺癌组织中的表达及临床意义 [J]. 交通医学, 2018, 32(3): 241-244.
10
赵轲, 张永建, 刘奇, 等. miR-107与非小细胞肺癌的临床病理特征及预后的关联 [J]. 中国医科大学学报, 2018, 47(10): 933-938.
11
Wei X, Lei Y, Li M, et al. miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway in vivo and vitro [J]. J Thorac Dis, 2020, 12(4): 1540-1551.
12
Moeng S, Seo HA, Hwang CY, et al. MicroRNA-107 targets IKBKG and sensitizes A549 cells to parthenolide [J]. Anticancer Res, 2018, 38(11): 6309-6316.
13
刘荷英, 王辉, 季洪健, 等. miR-107靶向细胞周期蛋白E1对人非小细胞肺癌A549细胞功能的影响研究 [J]. 重庆医学, 2018, 47(8): 1025-1028+1032.
14
吴瑕, 何君, 王文军. miR-107靶向NID2通过Notch信号通路调控肺癌细胞的增殖侵袭[J]. 中国免疫学杂志, 2017, 33(11): 1662-1667.
15
Wang P, Liu X, Shao Y, et al. MicroRNA-107-5p suppresses non-small cell lung cancer by directly targeting oncogene epidermal growth factor receptor [J]. Oncotarget, 2017, 8(34): 57012-57023.
16
Wu Z, Yuan Q, Yang C, et al. Downregulation of oncogenic gene TGFβR2 by miRNA-107 suppresses non-small cell lung cancer [J]. Pathol Res Pract, 2020, 216(1): 152690.
17
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
18
谈路轩, 李超, 曹伟军, 等. 胃癌与胃微生态的研究进展 [J]. 中国微生态学杂志, 2018, 30(8): 985-989.
19
Wang S, Lv C, Jin H, et al. A common genetic variation in the promoter of miR-107 is associated withgastric adenocarcinoma susceptibility and survival [J]. Mutat Res, 2014, 769: 35-41.
20
Song YQ, Ma XH, Ma GL, et al. MicroRNA -107 promotes proliferation of gastric cancer cells by targeting cyclin dependent kinase 8 [J]. Diagnostic Pathology, 2014, 9(1): 164.
21
Li X, Zhang Y, Shi Y, et al. MicroRNA -107,an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer [J]. J Cell Mol Med, 2011, 15(9): 1887-1895.
22
于志红, 张娟, 刘培民. miR-107靶向PCDH17表达调控EMT通路抑制胃癌细胞迁移、侵袭的分子机制 [J]. 中国老年学杂志, 2020, 40(7): 1508-1513.
23
余南荣, 曾祥, 徐厚巍, 等. MiR-107靶向Notch2促进胃癌细胞迁移和侵袭 [J]. 第三军医大学学报, 2019, 41(12): 1142-1148.
24
张肖丽, 张月晓, 陈健, 等. miR-107在胃癌中的表达及其对胃癌细胞生物学特性的影响 [J]. 解剖学研究, 2020, 42(1): 32-37.
25
Wang L, Li K, Wang C, et al. miR-107 regulates growth and metastasis of gastric cancer cells via activation of the PI3K-AKT signaling pathway by down-regulating FAT4 [J]. Cancer Med, 2019, 8: 5264-5473.
26
Ren W, Zhang X, Li W, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer [J]. Cancer Manag Res, 2019, 11: 4023-4040.
27
Cheng F, Yang Z, Huang F, et al. microRNA-107 inhibits gastric cancer cell proliferation and metastasis by targeting PI3K/AKT pathway [J]. Microb Pathog, 2018, 121: 110-114.
28
Jiang L, Zhang Y, Guo L, et al. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway [J]. BMC Cancer, 2021, 21(1): 1290.
29
Chen Y, Gong W, Zhou Y, et al.Metformin up-regulated miR-107 expression and enhanced the inhibitory effect of miR-107 on gastric cancer growth [J]. Transl Cancer Res 2020, 9(4): 2941-2950.
30
张肖丽, 张月晓, 李萍, 等. 胃癌组织中miR-107、AXIN2的表达及与预后的相关性 [J]. 临床与实验病理学杂志, 2021, 37(7): 798-802.
31
Chen P, Zhao X, Wang H, et al. The down-regulation of lncRNA PCAT18 promotes the progression of gastric cancer via MiR-107/PTEN/PI3K/AKT signaling pathway [J]. Onco Targets Ther, 2019, 12: 11017-11031.
32
刘慧玲, 谢华红. 过表达miR-107促进HT29细胞增殖和成瘤能力 [J]. 细胞与分子免疫学杂志, 2018, 34(10): 908-913.
33
Liu F, Liu S, Ai F, et al. miR-107 promotes proliferation and inhibits apoptosis of colon cancer cells by targeting prostate apoptosis response-4 (Par4) [J]. Oncol Res, 2017, 25(6): 967-974.
34
邹德胜, 刘卓, 茅利明.miR-103和miR-107在结直肠癌患者血清中的表达及其临床意义[J]. 中国卫生检验杂志, 2019, 29(3): 310-313.
35
张肖丽, 李炳庆, 张月晓, 等. 血清miR-107在结直肠癌患者中的表达及其诊断价值分析 [J]. 国际检验医学杂志, 2020, 41(1): 41-44+49.
36
Zhang J, Sun J, Liu J, et al. Correlation between microRNA-107 expression level and prognosis in patients with colorectal cancer [J]. Int J Clin Exp Pathol, 2020, 13(9): 2342-2347.
37
张肖丽, 张月晓, 李炳庆, 等. 结直肠癌组织及血清中miRNA-107相对表达水平与临床病理特征及预后的关系 [J]. 国际检验医学杂志, 2021, 42(19): 2379-2383.
38
Zhao M, Wang Y, Jiang C, et al. miR-107 regulates the effect of MCM7 on the proliferation and apoptosis of colorectal cancer via the PAK2 pathway [J]. Biochem Pharmacol, 2021, 190: 114610.
39
Kozovska Z, Gabrisova V, Kucerova L. Colon cancer:cancer stem cells markers, drug resistance and treatment [J]. Biomed Pharmacother, 2014, 24: 911-916.
40
Liang Y, Zhu D, Hou L, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39[J]. Br J Cancer.2020,122(5):705-714.
41
Fu Y, Lin L, Xia L. MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1 [J]. Cell Mol Biol Lett, 2019, 24: 31.
42
Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future [J]. Lancet Oncol, 2020, 21: e135-e145.
43
张军港, 洪德飞, 孙晓东, 等. MiR-107对胰腺癌细胞增殖和衰老的影响 [C]. 2015年浙江省外科学学术年会暨国家级肝胆胰疾病诊治进展学习班论文汇编, 2015: 155-156.
44
Xiong J, Wang D, Wei A, et al.Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN [J]. Exp Cell Res, 2017, 361(2): 316-323.
45
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71: 7-33.
46
Xiao D, Gao HX. Mechanism of miR-107-targeting of regulator of G-protein signaling 4 in hepatocellular carcinoma [J]. Oncol Lett, 2019, 18(5): 5145-5154.
47
贾振亚, 曹静, 范文洁, 等. miR-107对HepG2细胞增殖和细胞周期的影响 [J]. 安徽医科大学学报, 2014, 49(10): 1400-1404.
48
Chen HA, Li CC, Lin YJ, et al. Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells [J]. Aging (Albany NY), 2021, 13(8): 12046-12057.
49
Ali HEA, Emam AA, Zeeneldin AA, et al. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization [J]. Clin Biochem, 2019, 65: 45-52.
50
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71: 7-33.
51
Gao B, Hao S, Tian W, et al. MicroRNA-107 is downregulated and having tumor suppressive effect in breast cancer by negatively regulating brain-derived neurotrophic factor [J]. J Gene Med 2017, 19(12): e2932.
52
Ai H, Zhou W, Wang Z, et al. microRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1 [J]. J Cell Biochem, 2018: 1-10.
53
Zhang L, Ma P, Sun LM, et al. MiR-107 down-regulates SIAH1 expression in human breast cancer cells and silencing of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer [J]. Mol Carcinog, 2016, 55: 768-77.
54
Wang G, Ma C, Shi X, et al. miR-107 enhances the sensitivity of breast cancer cells to paclitaxel [J]. Open Med (Wars), 2019, 14: 456-466.
55
Luo Y, Hua T, You X, et al. Effects of MiR-107 on the Chemo-drug sensitivity of breast cancer cells [J]. Open Med (Wars), 2019, 14: 59-65.
56
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
57
王春桃, 何曙芝, 徐敏, 等. miRNA单核苷酸多态性与宫颈癌的相关性研究 [J]. 现代预防医学, 2017, 44(7): 1220-1224.
58
刘雅坤, 杜家宜, 赵运清. miR-107对宫颈癌细胞系HeLa生物学行为的影响 [J]. 中华实用诊断与治疗杂志, 2021, 35(10): 1001-1006.
59
Li GC, Xin L, Wang YS, et al. Long intervening noncoding 00467 RNA contributes to tumorigenesis by acting as a competing endogenous RNA against miR-107 in cervical cancer cells [J]. Am J Pathol, 2019, 189(11): 2293-2310.
60
Rui X, Xu Y, Huang Y, et al. lncRNA DLG1-AS1 promotes cell proliferation by competitively binding with miR-107 and ip-regulating ZHX1 expression in cervical cancer [J]. Cell Physiol Biochem, 2018, 49(5): 1792-1803.
61
Zhou Z, Xia N. LncRNA DCST1-AS1 sponges miR-107 to upregulate CDK6 in cervical squamous cell carcinoma [J]. Cancer Manag Res, 2020, 12: 7921-7928.
62
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer [J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41: 3-14.
63
Loginov VI, Burdennyy AM, Filippova EA, et al. Hypermethylation of miR-107, miR-130b, miR-203a, miR-1258 genes associated with ovarian cancer development and metastasis [J]. Mol Biol (Mosk), 2018, 52(5): 801-809.
64
Tang Z, Fang Y, Du R. MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer [J]. Biochem Biophys Res Commun, 2019, 512(2): 331-337.
65
杨宗元, 孙朝阳, 周波, 等. miR-107靶向调控Dicer1促进卵巢癌细胞系侵袭转移 [J]. 肿瘤防治研究, 2013, 40(7): 660-666.
66
孟桐羽, 赵涛, 宋玉霞, 等. miR-107在卵巢癌组织中的表达及其对VEGFA的影响 [J]. 河北医科大学学报, 2021, 42(7): 818-822.
67
Liu B, Yan L, Chi Y, et al. Long non-coding RNA AFAP1-AS1 facilitates ovarian cancer progression by regulating the miR-107/PDK4 axis [J]. J Ovarian Res, 2021, 4(1): 60.
68
Bao W, Zhang Y, Li S, et al. miR-107-5p promotes tumor proliferation and invasion by targeting estrogen receptor-α in endometrial carcinoma [J]. Oncol Rep, 2019, 41(3): 1575-1585.
69
章燕, 祝亚平, 鲍伟. 下调microRNA-107表达对人子宫内膜样腺癌Ishikawa细胞增殖迁移和侵袭的作用 [J]. 现代妇产科进展, 2018, 27(5): 330-333.
70
Siegel RL, Miller KD, Fuchs HE, et al.Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71: 7-33.
71
陈化磊, 卓小岸, 车宪平, 等. 快速康复外科应用于腹腔镜膀胱癌根治术的临床观察 [J]. 中国医师杂志, 2020, 22(3): 458-460.
72
王敏, 杨睿, 钟镇宇, 等. 环状RNA circTCF25通过miR-103a-3p/miR-107调控CDK6的表达促进膀胱癌的增殖和迁移 [J]. 中国细胞生物学学报, 2018, 40(6): 929-936.
73
Chen LQ, Yi CL, Liu DC, et al. Hsa_circ_0041103 induces proliferation, migration and invasion in bladder cancer via the miR-107/FOXK1 axis [J]. Eur Rev Med Pharmacol Sci, 2021, 25(3): 1282-1290.
74
宋南. 多个基因参与microRNA-107在透明细胞肾癌中发挥抑制作用 [D]. 北京: 中国人民解放军医学院, 2019.
75
Imamura T, Komatsu S, Ichikawa D, et al. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer [J]. Sci Rep, 2017, 7(1): 5708.
76
Zhang X, Jin K, Luo JD, et al. MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1 [J]. Neoplasma, 2019, 66: 704-716.
77
Lo HC, Hsu JH, Lai LC, et al. MicroRNA-107 enhances radiosensitivity by suppressing granulin in PC-3 prostate cancer cells [J]. Sci Rep, 2020, 10(1): 14584.
78
Pinho JD, Silva GEB, Teixeira Júnior AAL, et al.MIR-107, MIR-223-3P and MIR-21-5P Reveals Potential Biomarkers in Penile Cancer [J]. Asian Pac J Cancer Prev, 2020, 21(2): 391-397.
79
Liu J, Han Y, Hu S, et al. Circulating exosomal MiR-107 restrains tumorigenesis in diffuse large B-Cell lymphoma by targeting 14-3-3η [J]. Front Cell Dev Biol, 2021, 9: 667800.
80
Chen X, Xie X, Zhou W. CircCFL1/MiR-107 axis targeting HMGB1 promotes the malignant progression of diffuse large B-Cell lymphoma tumors [J]. Cancer Manag Res, 2020, 12: 9351-9362.
81
Jiang R, Zhang C, Liu G, et al. MicroRNA-107 promotes proliferation, migration, and invasion of osteosarcoma cells by targeting tropomyosin 1 [J]. Oncol Re, 2017, 25(8): 1409-1419.
82
Yu M, Guo D, Cao Z, et al. Inhibitory effect of microRNA-107 on osteosarcoma Malignancy through regulation of Wnt/β-catenin signaling in vitro [J]. Cancer Invest, 2018, 36(3): 175-184.
83
Chen J, Zhou X, Xiao Q, et al. MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β [J]. Hum Cell, 2018, 31(1): 42-49.
84
Sharma P, Saini N, Sharma R. miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42 [J]. Oncol Rep, 2017, 37(5): 3116-3127.
85
Zhou Z, Huang F. Long Non-coding RNA LINC00152 regulates cell proliferation, migration and invasion in esophageal squamous cell carcinoma via miR-107/Rab10 axis[J]. Onco Targets Ther, 2019, 12: 8553-8567.
86
Chang Z, Fu Y, Jia Y, et al. Circ-SFMBT2 drives the malignant phenotypes of esophageal cancer by the miR-107-dependent regulation of SLC1A5 [J]. Cancer Cell Int, 2021, 21(1): 495.
87
黄朝平, 王轶, 黄石, 等. 钙通道蛋白α2δ1及miR-107在喉癌组织中的表达和临床意义[J]. 现代肿瘤医学, 2021, 29(2):225-232.
88
Chen L, Xu Z, Zhao J, et al. H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo [J]. Cell Biol Int. 2021, 45(3): 674-685.
89
孙茂苍, 李鑫. miR-107抑制胶质瘤细胞的体外增殖、迁移和侵袭 [J]. 基础医学与临床, 2020, 40(6): 784-789.
90
Su PF, Song SQ. Regulation of mTOR by miR-107 to facilitate glioma cell apoptosis and to enhance cisplatin sensitivity [J]. Eur Rev Med Pharmacol Sci, 2018, 22(20): 6864-6872.
91
Wu J, Guo X, Xu D, et al. LINC00662 sponges miR-107 accelerating the invasiveness and proliferation of glioma cells [J]. J Cancer, 2020, 11(19): 5700-5712.
92
Li D, Chai L, Yu X, et al.The HOTAIRM1/miR-107/TDG axis regulates papillary thyroid cancer cell proliferation and invasion [J]. Cell Death Dis, 2020, 11(4): 227.
93
Na C, Li X, Zhang J, et al. miR-107 targets TRIAP1 to regulate oral squamous cell carcinoma proliferation and migration [J]. Int J Clin Exp Pathol, 2019, 12(5): 1820-1825.
94
Zhao G, Wei Z, Guo Y. MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma [J]. Biol Res, 2020, 53(1): 11.
95
裴向春, 王志莲. mi-RNA调控自噬在癌症中的作用 [J/OL]. 中华临床医师杂志(电子版), 2020, 14(10): 843-847.

URL    
[1] 吴疆, 刘嘉琦, 邢泽宇, 张梦璐, 冯轲昕, 贾梓淇, 李佳欣, 王杰, 王昕, 王翔. 乳腺癌合并多原发恶性肿瘤一例并文献复习[J]. 中华乳腺病杂志(电子版), 2023, 17(01): 55-59.
[2] 陈永胜, 朱健, 王军, 张永辉, 徐源佑, 丁璐璐, 陈建国, 樊健, 姚海蓉. 江苏省启东市育龄女性恶性肿瘤患者生存率变化趋势分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 363-372.
[3] 边策. 妇科恶性肿瘤术后淋巴囊肿的防治[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(03): 373-373.
[4] 樊丽超, 郭瑾瑛, 陈鑫. 野生型RET与RET/PTC融合基因检测对甲状腺乳头状癌中央区淋巴结清扫的指导意义[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 631-635.
[5] 瞿虎. 上尿路恶性肿瘤整体治疗方案[J]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(06): 0-0.
[6] 邢媛媛, 蒋军红, 谢海琴, 吕学东. 肺恶性肿瘤继发下呼吸道感染病原学特点及耐药分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 779-783.
[7] 赵延军, 张红军, 贾丽娟, 顾兴, 李文洁, 柴雅琴, 冯斐, 张海涛. 疑难肺部阴影临床与病理分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(01): 26-30.
[8] 杨美, 简亿, 方莉, 余枝娟, 张建勇. 肺鳞癌合并鼻部弥漫大B细胞淋巴瘤一例[J]. 中华肺部疾病杂志(电子版), 2022, 15(06): 926-928.
[9] 苏可, 曹亚娟, 彭进, 张来柱, 余德才. 转化治疗后腔镜根治性肝切除手术治疗晚期胆道肿瘤(Laennec入路)[J]. 中华腔镜外科杂志(电子版), 2023, 16(01): 49-51.
[10] 赵祺, 吕培华, 吴红林, 李勇, 汤明珠, 屈豪, 徐阳, 袁露, 郭永恒, 周洲, 高爽. 上消化道早癌筛查的研究进展[J]. 中华消化病与影像杂志(电子版), 2022, 12(03): 167-170.
[11] 王家圆, 王晓东. 消化系统恶性肿瘤相关肌少症的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 823-827.
[12] 吴一菡, 雷章, 卢宏达. MUC16/CA125在良恶性肿瘤诊治中的作用及其研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 591-595.
[13] 王亚飞, 吴振彪. 自身抗体在皮肌炎患者管理中的应用[J]. 中华临床医师杂志(电子版), 2022, 16(08): 796-800.
[14] 蔡朝蓓, 李惠凯, 高飞, 韩珂, 令狐恩强. 消化道恶性肿瘤活动性出血不同内镜下止血方法的对比研究[J]. 中华胃肠内镜电子杂志, 2023, 10(03): 152-158.
[15] 袁畅, 李志刚. 胸部恶性肿瘤相关气管食管瘘的诊治进展[J]. 中华胸部外科电子杂志, 2023, 10(04): 241-246.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号